World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
39997
World Ranking
15865
National Ranking
834

Overview

Arndt Vogel is affiliated with Hannover Medical School in Germany, contributing extensively to the field of medicine with a focus on oncology and hepatology. Their research spans a variety of topics related to cancer treatment, liver diseases, and cancer immunotherapy.

The scientist has been involved in significant research within these main fields of study:

  • Medicine

Their subfields of study include:

  • Oncology
  • Hepatology
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Epidemiology

Arndt Vogel's primary research topics cover:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Liver Disease Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Gallbladder and Bile Duct Disorders

Their publication record features numerous contributions to several key medical journals, including:

  • Journal of Clinical Oncology (67 publications)
  • Annals of Oncology (53 publications)
  • Journal of Hepatology (36 publications)
  • Zeitschrift für Gastroenterologie (16 publications)
  • Liver Cancer (11 publications)

Among their recent notable papers are:

  • "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study" (2020), The Lancet Oncology
  • "Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2022), Annals of Oncology
  • "NASH limits anti-tumour surveillance in immunotherapy-treated HCC" (2021), Nature
  • "Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial" (2023), The Lancet
  • "Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2022), Annals of Oncology

Collaboration has been an integral part of Vogel's work, with frequent co-authors including:

  • Anna Saborowski
  • Masatoshi Kudo
  • Lorenza Rimassa
  • Richard S. Finn
  • Bernhard Scheiner

Best Publications

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han

  • BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.

    M. Reig;A. Forner;J. Rimola;J. Ferrer-Fábrega

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Vaibhav Sahai;Antoine Hollebecque;Gina Vaccaro

  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Dominik Pfister;Dominik Pfister;Nicolás Gonzalo Núñez;Roser Pinyol;Olivier Govaere

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • A comparison of fibrosis progression in chronic liver diseases

    Thierry Poynard;Philippe Mathurin;Ching-Lung Lai;Dominique Guyader

  • Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.

    A. Vogel;E. Martinelli;A. Cervantes;I. Chau

  • Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis.

    Arndt Vogel;Christian P. Strassburg;Michael P. Manns

  • Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Sarah Berhane;Hidenori Toyoda;Toshifumi Tada;Takashi Kumada

  • Autoimmune hepatitis, from mechanisms to therapy.

    Michael P. Manns;Arndt Vogel

  • Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

    A. Vogel;A. Cervantes;I. Chau;B. Daniele

  • Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury.

    Jutta Lamlé;Silke Marhenke;Jürgen Borlak;Reinhard von Wasielewski

  • GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.

    Jan Best;Lars P. Bechmann;Jan-Peter Sowa;Svenja Sydor

  • Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.

    Ursula Ehmer;Arndt Vogel;Jan Karl Schütte;Britta Krone

  • Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

    Bernhard Scheiner;Katharina Pomej;Martha M. Kirstein;Florian Hucke

  • The RENAISSANCE (AIO-FLOT5) Trial: Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of the German AIO/CAO-V/CAOGI

    Salah-Eddin Al-Batran;Thorsten O Goetze;Daniel W. Mueller;Arndt Vogel

  • Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

    Lucie Heinzerling;Thomas K Eigentler;Michael Fluck;Jessica C Hassel

  • Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment

    Elad Horwitz;Ilan Stein;Mariacarla Andreozzi;Julia Nemeth

  • UDP Glucuronosyltransferase (UGT1A7) Gene Polymorphisms Increase the Risk of Chronic Pancreatitis and Pancreatic Cancer

    Johann Ockenga;Arndt Vogel;Niels Teich;Volker Keim

Frequent Co-Authors

Michael P. Manns
Michael P. Manns Hannover Medical School
Masatoshi Kudo
Masatoshi Kudo Kindai University
Christian P. Strassburg
Christian P. Strassburg University Hospital Bonn
Andrew X. Zhu
Andrew X. Zhu Harvard University
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Juan W. Valle
Juan W. Valle University of Manchester
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Robert Geffers
Robert Geffers Helmholtz Centre for Infection Research
Stephen L. Chan
Stephen L. Chan Chinese University of Hong Kong
Josep M. Llovet
Josep M. Llovet University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering alternative pathways in the medical field? Many students start with accessible healthcare programs to build foundational skills or jumpstart their careers. For example, medical billing and coding schools with financial aid offer a fast, affordable entry into healthcare administration, often completed fully online.

Those interested in patient care, but who want to avoid intense entrance testing, can explore nursing school no entrance exam programs. These options make nursing more accessible for qualifying students.

For leadership-minded individuals, the best online healthcare administration degree programs provide flexible learning and direct pathways to administrative roles in hospitals, clinics, and other care settings.

Registered nurses looking to advance further can benefit from adn to fnp bridge programs, which make it possible to become a Family Nurse Practitioner without starting over.

These diverse remote and hybrid health degrees expand your career options and make studying medicine in the USA more accessible than ever.

Best Scientists Citing Arndt Vogel

Trending Scientists